colorectal cancer
Conditions
Interventions
Treatment group:CapeOx or FOLFOX + KangYanJingFang for Stage II High Risk - Stage III postoperative patients with colorectal cancer, 6 months observation.
Composition of KangYanJingFang: 15g of Radix
Control group:Stage II high-risk postoperative patients with stage III colorectal cancer treated with CapeOx or FOLFOX chemotherapy regimens for six months
Sponsors
Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) After radical surgery for colorectal cancer; (2) Age between 18 and 75 years old; (3) Western medical diagnosis in accordance with the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) staging, with TNM staging of stage II high-risk-stage III requiring chemotherapeutic treatment; (4) Expected survival of more than 6 months (5) Subjects with normal cognitive function and no dysfunction of major organs. (6) Agree to comply with the study protocol, sign the informed consent form, and complete the study according to the protocol requirements.
Exclusion criteria
Exclusion criteria: (1) Those with a combined history of other malignancies; (2) Those with severe or uncontrolled medical disorders and infections; (3) Are participating in other clinical studies or have participated in other clinical studies within 1 month; (4) Allergic patients; (5) Pregnant and lactating women; (6) Those with a history of psychiatric disorders that cannot be easily controlled; (7) Patients receiving radiotherapy treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemotherapy completion rate;Chinese Medicine Score;Cancer Fatigue Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Karnofsky Performance Status; | — |
Countries
China
Contacts
Public ContactZhenye Xu
Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed